Monthly Archives: May 2024

INTRODUCTION Colorectal cancer is responsible for the second highest mortality among all cancer types and primarily affects adults aged 70 years or older. Due to the aging global population, the number of older adults with cancer, including colorectal cancer, is rapidly increasing. Although the majority of patients with metastatic colorectal cancer (mCRC) are older than 70 years, there are very few clinical trials specifically focused on this large patient group. The investigator-initiated randomized phase II NORDIC9-study prospectively assessed an approach for older patients with mCRC who were not considered candidates for full-dose combination treatment, comparing reduced-dose combination therapy to full-dose single-agent chemotherapy. NORDIC9 included 160 patients from four Nordic countries between March 2015 and October 2017. The study established that reduced-dose combination chemotherapy resulted in significantly prolonged progression-free survival, with a trend towards prolonged overall survival, fewer toxicities, and fewer hospital admissions compared to full-dose monotherapy. Additionally, patients receiving reduced-dose [...]